Dublin City University
|As first author||27|
|As last author||7|
Kenneth J O'Byrne(4)
... and 53 others
These arethe9 unique sources for Paul Dowling's 79 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.
|Ireland -> Dublin City University||40|
|Ireland -> Dublin City University -> PubMed||37|
|Ireland -> Maynooth University||42|
|Ireland -> Maynooth University -> PubMed||8|
|Ireland -> Royal College of Surgeons in Ireland||1|
|Ireland -> Trinity College Dublin||6|
|Ireland -> Trinity College Dublin -> PubMed||2|
|Ireland -> University College Dublin||8|
|Ireland -> University College Dublin -> PubMed||8|
A method of monitoring a breast cancer patient's response to treatment, or of detecting recurrence of breast cancer, the method comprising a step of assaying a plurality of samples obtained from the patient over a period of time for expression levels of a plurality of biomarkers including Cancer Antigen 15-3 (CA 15-3) and one of either Glutamate or 12-Hydroxyeicosatetraenoic acid (12-HETE), and detecting a change in expression levels of CA 15-3 and one (or both) of either Glutamate or 12-HETE over the time period, wherein detection of a decreased expression levels of CA 15-3 and one of either Glutamate or 12-HETE over the time period is indicative of a response to therapy and wherein detection of increased or stable expression levels of CA 15-3 and one of either Glutamate or 12-HETE over the time period is indicative of a non-response to breast cancer therapy.
A method of predicting response to thalidomide, or thalidomide analogs, in an individual with cancer, especially cancers for which thalidomide has been implicated as a treatment, such as Multiple Myeloma (MM) employs one or more of a panel of biomarkers that have been shown to be differentially expressed in cancer patients that respond to thalidomide (hereafter "Responders") relative to cancer patients that do not respond to thalidomide (hereafter "Non-responders). The method involves assaying a biological sample from the individual to determine the abundance of at least three biomarkers including Vitamin-D binding protein precursor(VDB) (Sequence ID 1) and Serum amyloid A protein (SAA) (Sequence ID 3), and at least one of beta-2-microglobulin (B2M) (Sequence ID 4), Haptoglobin (Hp) precursor (fragment) (Sequence ID 5), and zinc-alpha-2- glycoprotein (ZAG) (Sequence ID 2). Correlation of the abundance value for the at least three biomarkers with a reference abundance value from a Responder or Non-responder enables predication of response to thalidomide for the patient.
A method for the inhibition, prevention or treatment of invasive/metastatic cancer in an individual in need thereof, comprises a step of treating the individual with an agent capable of attenuating the activity of protein selected from the group consisting of: STIPl
The invention relates to a method of screening patients to identify patients at risk of having a lung squamous cell carcinoma. A sample of serum from the individual is assayed for the abundance of a protein selected from the group consisting of: SEQUENCE ID NO'S: 1 to 11 relative for a control abundance for that protein, and the relative abundance obtained is correlated with risk of lung SCC cancer. The diagnosis may involve a single diagnostic variable or a panel of diagnostic variables. For each biomarker, relative abundance may be obtained by means of 2-DIGE separation and gel imaging. The samples are generally pre-treated to remove highly abundant proteins from the serum.
Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.
Here is a quick breakdown of this expert's publication history
If this is the expert you have been looking for, simply click here to make contact.